Publicaciones en las que colabora con Rafael Rubio García (22)

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2015

  1. Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

    PLoS ONE, Vol. 10, Núm. 10

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

  3. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  4. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions

    PLoS ONE, Vol. 9, Núm. 12

  2. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

  3. Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes

    International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6

2012

  1. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial

    Journal of Infectious Diseases, Vol. 206, Núm. 6, pp. 961-968

2010

  1. Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C

    AIDS Research and Human Retroviruses, Vol. 26, Núm. 4, pp. 419-424

2009

  1. (Enfermedades Infecciosas y Microbiologia Clinica (2009) 27, 4, (222-235))

    Enfermedades Infecciosas y Microbiologia Clinica

  2. Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality

    Current HIV Research, Vol. 7, Núm. 2, pp. 224-230

2008

  1. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313

2007

  1. Cohorte RIS de pacientes con infección por VIH sin tratamiento antirretroviral previo (CoRIS): Metodología y primeros resultados

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 25, Núm. 1, pp. 23-31

2004

  1. Consensus conference on chronic viral hepatitis and HIV infection: Updated Spanish recommendations

    Journal of Viral Hepatitis

2002

  1. Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999

    Sexually Transmitted Infections, Vol. 78, Núm. 4, pp. 255-260

2001

  1. GESIDA Consensus document on the use of resistance studies in clinical practice

    Enfermedades infecciosas y microbiología clínica

2000

  1. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain

    AIDS, Vol. 14, Núm. 6, pp. 727-732